Global prevalence of multiple sclerosis surpasses 3 million: 2024 update of the Multiple Sclerosis International Federation Atlas of MS
Multiple Sclerosis Journal · 2026-11 · 32 (13) · 1365-1374
DOI: 10.1177/13524585261479954 ↗Kurz gefasst
Fachartikel in der Zeitschrift Multiple Sclerosis Journal, online erschienen am 03.09.2026. Verfasst von Rachel King und 6 weiteren Autor:innen. Beteiligte Einrichtung: Multiple Sclerosis International Federation (MSIF), London, UK. Hauptthemen laut MEDLINE: Multiple Sclerosis, Global Health. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Bristol-Myers Squibb, Novartis, Associazione Italiana Sclerosi Multipla.
Abstract (Originalsprache)
Background
The Atlas of MS provides a dataset on multiple sclerosis. This analysis updates the global prevalence (including separate estimates for pediatric multiple sclerosis) and incidence of multiple sclerosis, and examines changes over time using data from 2013, 2020, and 2024.
Methods
Countries participating in the 2024 Atlas update confirmed or updated epidemiological data. Global prevalence was estimated using submitted case counts supplemented with pooled subregional rates and, for 2020 and 2024, literature-based imputation.
Results
Experts in 133 countries representing 93% of the global population participated. Prevalence data were provided by 118 countries. Global multiple sclerosis prevalence per 100,000 rose from 24.8 (95% confidence interval: 24.73–24.80) in 2013 to 38.1 (95% confidence interval: 38.09–38.17) in 2024 and most regions showed rising prevalence; 3.1 million people now live with multiple sclerosis globally. Higher-income countries reported higher prevalence than lower-income countries. The number of reported pediatric multiple sclerosis cases increased from 7,000 in 2013 to >40,000 in 2024. Incidence data provided by 91 countries estimated that 120,000 new diagnoses occur annually.
Conclusion
Global multiple sclerosis prevalence continues to rise. Strengthened and equitable data collection is essential as diagnostic criteria evolve, and these findings provide a benchmark before widespread adoption of the 2024 McDonald criteria.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Multiple Sclerosis International Federation (MSIF), London, UK.
- Departments of Medicine and Community Health and Epidemiology, Faculty of Medicine, Dalhousie University, Halifax, NS, Canada.
- Departments of Medicine, Nova Scotia Health Authority, Halifax, Canada.
- Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia.
- Department of Pediatrics, Johns Hopkins School of Medicine, Baltimore, MD, USA.
ORCID-Profile: Rachel King, Ruth Ann Marrie, Ingrid van der Mei, Brenda Banwell, Lydia Makaroff, Nick Rijke, Anne Helme
Förderung
- Bristol-Myers Squibb
- Novartis
- Associazione Italiana Sclerosi Multipla
- Biogen
- Viatris
- Deutschen Multiple Sklerose Gesellschaft
- Merck
- Multiple Sclerosis Society
Zitieren
APA
King, R., Marrie, R. A., van der Mei, I., Banwell, B., Makaroff, L., Rijke, N., & Helme, A. (2026). Global prevalence of multiple sclerosis surpasses 3 million: 2024 update of the Multiple Sclerosis International Federation Atlas of MS. Multiple Sclerosis Journal, 32(13), 1365-1374. https://doi.org/10.1177/13524585261479954
Vancouver
King R, Marrie RA, van der Mei I, Banwell B, Makaroff L, Rijke N, et al. Global prevalence of multiple sclerosis surpasses 3 million: 2024 update of the Multiple Sclerosis International Federation Atlas of MS. Multiple Sclerosis Journal. 2026;32(13):1365-1374. doi:10.1177/13524585261479954
BibTeX
@article{King2026,
author = {King, Rachel and Marrie, Ruth Ann and van der Mei, Ingrid and Banwell, Brenda and Makaroff, Lydia and Rijke, Nick and Helme, Anne},
title = {Global prevalence of multiple sclerosis surpasses 3 million: 2024 update of the Multiple Sclerosis International Federation Atlas of MS},
journal = {Multiple Sclerosis Journal},
year = {2026},
volume = {32},
number = {13},
pages = {1365--1374},
doi = {10.1177/13524585261479954}
}
EUVIMED